Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (201-210 of 350) with videos related to

Pageof 35
Sort By:
Iscience|December 21, 2023
SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesityMona Farhadipour, Kaline Arnauts, Mathias Clarysse, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
European Journal of Gastroenterology & Hepatology|May 27, 2020
Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international surveyWebber Chan, Viraj C Kariyawasam, Shin Kim, et al.
Gastroenterology|December 14, 2005
Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBDSéverine Vermeire, Marie Pierik, Tibor Hlavaty, et al.
Clinical Nutrition ESPEN|May 9, 2026
Feasibility assessment of an emulsifier-free diet in healthy subjects - a sub-analysis of the FOAM trialJudith Wellens, Martijn Luppens, Sien Hoekx, et al.
BMC Medical Informatics and Decision Making|November 18, 2022
Using provocative design to foster electronic informed consent innovationEvelien De Sutter, Stef Verreydt, Koen Yskout, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk ModelPeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Inflammatory Bowel Diseases|January 9, 2007
Predictors of early response to infliximab in patients with ulcerative colitisMarc Ferrante, Séverine Vermeire, Konstantinos H Katsanos, et al.
Frontiers in Immunology|September 28, 2020
Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype EquilibriumBrecht Creyns, Inge Jacobs, Bram Verstockt, et al.
Journal of Crohn'S & Colitis|August 30, 2024
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III TrialsRemo Panaccione, Christopher Ma, Vipul Jairath, et al.
Pageof 35

Showing results (201-210 of 350) with videos related to

Sort By:
Pageof 35
Iscience|December 21, 2023
SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesityMona Farhadipour, Kaline Arnauts, Mathias Clarysse, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
European Journal of Gastroenterology & Hepatology|May 27, 2020
Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international surveyWebber Chan, Viraj C Kariyawasam, Shin Kim, et al.
Gastroenterology|December 14, 2005
Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBDSéverine Vermeire, Marie Pierik, Tibor Hlavaty, et al.
Clinical Nutrition ESPEN|May 9, 2026
Feasibility assessment of an emulsifier-free diet in healthy subjects - a sub-analysis of the FOAM trialJudith Wellens, Martijn Luppens, Sien Hoekx, et al.
BMC Medical Informatics and Decision Making|November 18, 2022
Using provocative design to foster electronic informed consent innovationEvelien De Sutter, Stef Verreydt, Koen Yskout, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk ModelPeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Inflammatory Bowel Diseases|January 9, 2007
Predictors of early response to infliximab in patients with ulcerative colitisMarc Ferrante, Séverine Vermeire, Konstantinos H Katsanos, et al.
Frontiers in Immunology|September 28, 2020
Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype EquilibriumBrecht Creyns, Inge Jacobs, Bram Verstockt, et al.
Journal of Crohn'S & Colitis|August 30, 2024
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III TrialsRemo Panaccione, Christopher Ma, Vipul Jairath, et al.
Pageof 35